Precision Medicine for Idiopathic Hypersomnia.
Central Nervous System Stimulants
/ therapeutic use
Clarithromycin
/ therapeutic use
Flumazenil
/ therapeutic use
GABA Modulators
/ therapeutic use
Humans
Idiopathic Hypersomnia
/ drug therapy
Mazindol
/ therapeutic use
Modafinil
/ therapeutic use
Orexins
/ metabolism
Piperidines
/ therapeutic use
Polysomnography
Precision Medicine
Sleep
Sodium Oxybate
/ therapeutic use
Wakefulness
Wakefulness-Promoting Agents
/ therapeutic use
Drowsiness
GABA
Hypersomnia
Long sleep time
Modafinil
Sodium oxybate
Journal
Sleep medicine clinics
ISSN: 1556-4088
Titre abrégé: Sleep Med Clin
Pays: United States
ID NLM: 101271531
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
entrez:
4
8
2019
pubmed:
4
8
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Idiopathic hypersomnia (IH) is characterized by excessive daytime sleepiness despite normal or prolonged sleep. IH is distinguished from narcolepsy by the female predominance, severe morning inertia, continuous drowsiness (rather than sleep attacks), unrefreshing naps, absence of cataplexy, sleep onset in REM periods, and hypocretin deficiency. In IH, the multiple sleep latency test demonstrates low sensitivity, specificity, and reproducibility, compared with prolonged sleep monitoring. In some IH cases, an endogenous hypnotic peptide stimulating GABA receptors during wakefulness is suspected, which are improved by anti-GABA drugs. The benefits of modafinil, sodium oxybate, mazindol, and pitolisant were found in mostly retrospective studies.
Identifiants
pubmed: 31375202
pii: S1556-407X(19)30048-7
doi: 10.1016/j.jsmc.2019.05.007
pii:
doi:
Substances chimiques
Central Nervous System Stimulants
0
GABA Modulators
0
HCRT protein, human
0
Orexins
0
Piperidines
0
Wakefulness-Promoting Agents
0
Flumazenil
40P7XK9392
pitolisant
4BC83L4PIY
Sodium Oxybate
7G33012534
Mazindol
C56709M5NH
Clarithromycin
H1250JIK0A
Modafinil
R3UK8X3U3D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-350Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.